Drug Interactions Database

944 interactions from BNF 85 - Check your medicines

Source: BNF 85

Severity: All 6278 Severe 944 Moderate 1418 Unknown 3916

stjohn’swort venetoclax

decreases exposure

Severe Study

stjohn’swort vinflunine

decreases exposure

Severe Theoretical

stjohn’swort vismodegib

decreases exposure

Severe Theoretical

stjohn’swort voriconazole

decreases exposure

Severe Study

stjohn’swort voxelotor

decreases exposure

Severe Theoretical

stjohn’swort voxilaprevir

decreases concentration

Severe Theoretical

stjohn’swort zanubrutinib

decreases exposure

Severe Theoretical

strontium quinolones

decreases absorption

Severe Theoretical

strontium tetracyclines

decreases absorption

Severe Theoretical

sulpiride dopaminereceptoragonists

decreases effects

Severe Theoretical

sympathomimetics,vasoconstrictor apraclonidine

decreases effects

Severe Theoretical

sympathomimetics,vasoconstrictor(adrenaline/epinephrine, ephedrine,isometheptene,noradrenaline/norepinephrine, phenylephrine linezolid

increases risk of elevatedbloodpressure

Severe Theoretical

tacrolimus dabigatran

increases exposure

Severe Theoretical

tacrolimus thrombininhibitors

increases exposure

Severe Theoretical

tacrolimus tofacitinib

increases exposure

Severe Study

tedizolid atorvastatin

increases exposure

Severe Study

tedizolid fluvastatin

increases exposure

Severe Study

tedizolid methotrexate

increases exposure

Severe Theoretical

tedizolid rosuvastatin

increases exposure

Severe Study

tedizolid statins

increases exposure

Severe Study

theophylline phosphodiesterasetype-

increases exposure

Severe Theoretical

theophylline roflumilast

increases exposure

Severe Theoretical

tipranavir tenofoviralafenamide

decreases exposure

Severe Theoretical

tretinoin vitamin

increases risk of vitaminatoxicity

Severe Study

triamterene pralsetinib

increases exposure

Severe Study

tricyclicantidepressants moclobemide

increases risk of severetoxicreaction

Severe Theoretical

tucatinib phosphodiesterasetype-

increases exposure

Severe Theoretical

valproate penicillins

increases risk of adverseeffects

Severe Anecdotal

valproate pivmecillinam

increases risk of adverseeffects

Severe Anecdotal

vandetanib fidaxomicin

increases exposure

Severe Study

velpatasvir dabigatran

increases exposure

Severe Study

velpatasvir thrombininhibitors

increases exposure

Severe Study

vemurafenib fidaxomicin

increases exposure

Severe Study

vemurafenib tizanidine

increases exposure

Severe Study

verapamil betablockers,non-selective

increases risk of cardiovascularadverseeffects

Severe

voriconazole bosentan

increases exposure

Severe Theoretical

voriconazole clopidogrel

decreases efficacy

Severe Study

voriconazole endothelinreceptorantagonists

increases exposure

Severe Theoretical

voxilaprevir sulfasalazine

increases concentration

Severe Theoretical

voxilaprevir topotecan

increases concentration

Severe Theoretical

voxilaprevirwithsofosbuvirandvelpatasvir levothyroxine

increases absorption

Severe Study

voxilaprevirwithsofosbuvirandvelpatasvirmarkedly rosuvastatin

increases exposure

Severe Study

voxilaprevirwithsofosbuvirandvelpatasvirmarkedly statins

increases exposure

Severe Study

zuclopenthixol dopaminereceptoragonists

decreases effects

Severe Theoretical

Prev 1 ... 17 18 19

944 interactions

Important: This database uses data from the British National Formulary (BNF 85). It is for informational purposes only and is not a substitute for professional medical advice.